These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 20973982

  • 1. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 2. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 03; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

  • 4. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 03; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 6. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 May 20; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 20; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 8. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.
    Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J.
    Br J Cancer; 2003 Jun 16; 88(12):1851-8. PubMed ID: 12799626
    [Abstract] [Full Text] [Related]

  • 9. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 16; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 10. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun 16; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.
    Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.
    Clin J Am Soc Nephrol; 2010 Apr 16; 5(4):598-606. PubMed ID: 20185602
    [Abstract] [Full Text] [Related]

  • 12. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Apr 16; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 13. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, Shavkin A, Srivaths P, Wong CJ, Petersen J.
    Pediatr Nephrol; 2018 Jan 16; 33(1):125-137. PubMed ID: 28815341
    [Abstract] [Full Text] [Related]

  • 14. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov 16; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 15. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec 16; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 16. Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
    Feriani M, De Meester JM, McMahon LP, Rottembourg JB, Bridges I, Farouk M, Pronai W.
    BMC Nephrol; 2011 Mar 24; 12():13. PubMed ID: 21435267
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep 24; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 24; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 19. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis.
    Nagaya H, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Hamaguchi K, Tatematsu M, Suzuki S, Kurata K, Yuzawa Y, Matsuo S.
    Clin Exp Nephrol; 2010 Apr 24; 14(2):158-63. PubMed ID: 19967423
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Apr 24; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.